Bullfrog AI (NASDAQ:BFRG) and Patient Portal Technologies (OTCMKTS:PPRG) Critical Comparison

Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Bullfrog AI and Patient Portal Technologies, as provided by MarketBeat.com.

Given Patient Portal Technologies’ higher probable upside, analysts clearly believe Patient Portal Technologies is more favorable than Bullfrog AI.

Earnings and Valuation

This table compares Bullfrog AI and Patient Portal Technologies”s revenue, earnings per share and valuation.

Patient Portal Technologies has lower revenue, but higher earnings than Bullfrog AI.

Volatility and Risk

Bullfrog AI has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Patient Portal Technologies has a beta of 3.77, indicating that its stock price is 277% more volatile than the S&P 500.

Institutional & Insider Ownership

1.0% of Bullfrog AI shares are held by institutional investors. 25.2% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Bullfrog AI and Patient Portal Technologies’ net margins, return on equity and return on assets.

About Bullfrog AI

(Get Free Report)

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Patient Portal Technologies

(Get Free Report)

Patient Portal Technologies, Inc. provides patient relationship management solutions for healthcare facilities, patients and families, and medical personnel. It offers HEALTHCAST, a multi-channel, television network for the delivery of customized information and education to patients, visitors, and staff; MEDEX PRESCRIPTION DELIVERY, a free prescription medication delivery solution; and PHONE & TV RENTAL, an interactive communication center, and billing and collection platform. The company also provides TELCIERGE INSTANT RESPONSE that puts patients in control of non-medical needs through a single phone call; QUICK PULSE SURVEYS that provide feedback for improved operations; and MEDCLIPS, which provide condition specific video clips for internal or remote viewing before or after hospital stay. Patient Portal Technologies, Inc. is based in Baldwinsville, New York.